iBio Announces Pricing of $35 Million Public Offering of Common Stock

NEXT STORY
Story Health Launches Virtual Specialty Care to Empower Patient-Clinician Relationship
PREV STORY
Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ADMA Biologics Reports Successful Close-Out of its April 2018 FDA Compliance Inspection

FDA Establishment Inspection Report (“EIR”) ReceivedRAMSEY, N.J. and BOCA RATON, Fla., July 26, 2018 ...

author_avatar
NASDAQ Market News

Cooper University Health Care First Hospital Site in the Nation to Host Training Program for Elite U.S. Army Resuscitation Forward Surgical Team

Camden, NJ, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Cooper University Health Care recently entered ...

author_avatar
NASDAQ Market News

Global Infectious Disease Diagnostics Market Will Reach USD 21286.18 Million By 2024: Zion Market Research

According to the report, the global infectious disease diagnostics market was valued at approximately ...

author_avatar
NASDAQ Market News